Wall Street analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to post earnings per share (EPS) of ($0.12) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Galectin Therapeutics’ earnings. Galectin Therapeutics reported earnings of ($0.07) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 71.4%. The company is scheduled to issue its next quarterly earnings report on Thursday, April 4th.
On average, analysts expect that Galectin Therapeutics will report full year earnings of ($0.44) per share for the current year. For the next financial year, analysts forecast that the company will report earnings of ($1.12) per share. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Galectin Therapeutics.
Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings data on Tuesday, November 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.02.
GALT stock opened at $4.97 on Wednesday. Galectin Therapeutics has a 1-year low of $1.80 and a 1-year high of $9.49.
In related news, Director Gilbert S. Omenn sold 19,370 shares of the stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $6.02, for a total transaction of $116,607.40. Following the sale, the director now directly owns 56,561 shares in the company, valued at approximately $340,497.22. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 38.80% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GALT. Millennium Management LLC bought a new stake in Galectin Therapeutics during the 1st quarter worth approximately $454,000. Belpointe Asset Management LLC bought a new stake in Galectin Therapeutics during the 2nd quarter worth approximately $277,000. First Allied Advisory Services Inc. bought a new stake in Galectin Therapeutics during the 2nd quarter worth approximately $223,000. BlackRock Inc. grew its position in Galectin Therapeutics by 199.9% during the 2nd quarter. BlackRock Inc. now owns 588,308 shares of the company’s stock worth $3,742,000 after acquiring an additional 392,151 shares during the last quarter. Finally, ING Groep NV bought a new stake in Galectin Therapeutics during the 2nd quarter worth approximately $318,000. Institutional investors and hedge funds own 14.36% of the company’s stock.
Galectin Therapeutics Company Profile
Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease, skin disease, and cancer. The company's lead product candidate includes galectin-3 inhibitor (GR-MD-02), a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.
See Also: Cost of Equity For A Business, Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.